Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia
This study has been completed.
Information provided by:
First received: June 20, 2008
Last updated: August 30, 2010
Last verified: August 2010
The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Multi-center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia|
Resource links provided by NLM:
Further study details as provided by Luitpold Pharmaceuticals:
Contacts and Locations